OTC SUPPLEMENTAL APPLICATIONS WILL REMAIN UNDER PRIMARY PURVIEW OF NEW DRUG REVIEW DIVISIONS: FDAers SEIFE, TEMPLE AND BILSTAD EXPLAIN Rx-TO-OTC

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".